Literature DB >> 4404325

Purification of pneumolysin.

C N Shumway, S J Klebanoff.   

Abstract

A procedure for the purification of pneumolysin has been developed. Its use results in a 96-fold increase in specific activity from the original crude pneumococcal extract to the final purified product. The purified material is heat-labile and is inactivated by trypsin and cholesterol; inactivation by p-hydroxymercuribenzoate can be reversed by mercaptoethanol. Intravenous administration of the material to rabbits results in crenation, increased osmotic fragility, and intravascular lysis of the erythrocytes of the animal.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4404325      PMCID: PMC416318          DOI: 10.1128/iai.4.4.388-392.1971

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  5 in total

1.  THE EFFECT OF A PNEUMOCOCCAL PRODUCT UPON RABBIT ERYTHROCYTES IN VITRO AND IN VIVO.

Authors:  C N SHUMWAY; D POLLOCK
Journal:  J Lab Clin Med       Date:  1965-03

2.  Spherocytic hemolytic anemia associated with acute pneumococcal infection in rabbits.

Authors:  C N SHUMWAY
Journal:  J Lab Clin Med       Date:  1958-02

3.  Pneumococcal Hemolysin: The Preparation of Concentrates, and Their Action on Red Cells.

Authors:  B Cohen; S P Halbert; M E Perkins
Journal:  J Bacteriol       Date:  1942-05       Impact factor: 3.490

4.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

5.  Physical behavior of pneumolysin.

Authors:  A S Kreger; A W Bernheimer
Journal:  J Bacteriol       Date:  1969-04       Impact factor: 3.490

  5 in total
  9 in total

1.  Pneumolysin, the thiol-activated toxin of Streptococcus pneumoniae, does not require a thiol group for in vitro activity.

Authors:  F K Saunders; T J Mitchell; J A Walker; P W Andrew; G J Boulnois
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

2.  Production and purification of Streptococcus pneumoniae hemolysin (pneumolysin).

Authors:  K Kanclerski; R Möllby
Journal:  J Clin Microbiol       Date:  1987-02       Impact factor: 5.948

3.  Moxifloxacin and cholesterol combined treatment of pneumococcal keratitis.

Authors:  Melissa E Sanders; Nathan A Tullos; Sidney D Taylor; Erin W Norcross; Lauren B King; Isaiah Tolo; Mary E Marquart
Journal:  Curr Eye Res       Date:  2010-12       Impact factor: 2.424

4.  Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae.

Authors:  J C Paton; R A Lock; D J Hansman
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

5.  Toxicity of pneumolysin to pulmonary endothelial cells in vitro.

Authors:  J B Rubins; P G Duane; D Charboneau; E N Janoff
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

6.  High-molecular-weight hemolysin of Clostridium tetani.

Authors:  K Mitsui; N Mitsui; K Kobashi; J Hase
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

7.  Properties of purified pneumococcal hemolysin.

Authors:  M K Johnson
Journal:  Infect Immun       Date:  1972-11       Impact factor: 3.441

8.  Critical involvement of pneumolysin in production of interleukin-1alpha and caspase-1-dependent cytokines in infection with Streptococcus pneumoniae in vitro: a novel function of pneumolysin in caspase-1 activation.

Authors:  Shereen Shoma; Kohsuke Tsuchiya; Ikuo Kawamura; Takamasa Nomura; Hideki Hara; Ryosuke Uchiyama; Sylvia Daim; Masao Mitsuyama
Journal:  Infect Immun       Date:  2008-01-14       Impact factor: 3.441

9.  Mouse, but not human, ApoB-100 lipoprotein cholesterol is a potent innate inhibitor of Streptococcus pneumoniae pneumolysin.

Authors:  Kristin R Wade; Eileen M Hotze; David E Briles; Rodney K Tweten
Journal:  PLoS Pathog       Date:  2014-09-04       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.